JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266858

Human EIF1 knockout HCT116 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

EIF1 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

View Alternative Names

EIF1_HUMAN, Eukaryotic translation initiation factor 1, ISO1, Protein translation factor SUI1 homolog, SUI1, Sui1iso1, eIF-1A

2 Images
Sanger Sequencing - Human EIF1 knockout HCT116 cell line (AB266858)
  • Sanger seq

Unknown

Sanger Sequencing - Human EIF1 knockout HCT116 cell line (AB266858)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human EIF1 knockout HCT116 cell line (AB266858)
  • Sanger seq

Unknown

Sanger Sequencing - Human EIF1 knockout HCT116 cell line (AB266858)

Allele-1 : 16 bp deletion in exon1

Key facts

Cell type

HCT116

Species or organism

Human

Tissue

Colon

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Carcinoma

Product details

Recommended control: Human wild-type HCT116 cell line (ab255451). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266858-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266858 Human EIF1 knockout HCT116 cell line", "number":"AB266858-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266858-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266858 Human EIF1 knockout HCT116 cell line", "number":"AB266858-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
EIF1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

McCoY5a + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EIF1 also known as 'eukaryotic translation initiation factor 1' plays a vital role in the initiation of protein synthesis. Its molecular mass is approximately 12 kDa. eIF1 functions mechanically by binding to the 40S ribosomal subunit which is essential for recruiting the initiation codon and maintaining the fidelity of start site selection during translation. Expression of eIF1 occurs in various tissues particularly higher in proliferative cells due to its role in protein synthesis.
Biological function summary

Eukaryotic translation initiation factor 1 facilitates the formation of the translation pre-initiation complex. It is an integral component of the eIF1A- and eIF2-associated assembly that is important for the proper translation initiation. This factor acts to stabilize the pre-initiation complex by preventing premature joining with the 60S ribosomal subunit ensuring accurate translation initiation sites are selected across a range of mRNAs.

Pathways

EIF1 is primarily involved in the mRNA translation initiation pathway. This pathway is important for regulating protein synthesis and gene expression. eIF1 interacts closely with other initiation factors like eIF2 which carries the initiator methionyl-tRNA and eIF3 which binds to the 40S ribosomal subunit to form the functional ribosome assembly. Additionally eIF1's role in translation initiation is also linked to cellular stress responses influencing how cells adapt to changing environmental conditions.

Aberrant expression or malfunction of eIF1 may contribute to cancer and neurological disorders. Overexpression of eIF1 has been observed in some types of cancer suggesting a connection with tumorigenesis due to uncontrolled protein synthesis. Additionally eIF1's interaction with other transcription factors could influence neurodegenerative diseases where disruptions in protein homeostasis are an important feature. Understanding eIF1's role could therefore aid in developing novel therapeutic strategies for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com